| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 25 | 2024 | 621 | 5.910 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 22 | 2024 | 1192 | 3.250 |
Why?
|
| Gastrointestinal Microbiome | 11 | 2025 | 820 | 2.520 |
Why?
|
| Dysbiosis | 5 | 2025 | 141 | 1.110 |
Why?
|
| Bacteroides | 2 | 2024 | 37 | 1.060 |
Why?
|
| Thrombospondins | 2 | 2018 | 14 | 0.700 |
Why?
|
| Metabolome | 2 | 2025 | 324 | 0.630 |
Why?
|
| Gastrointestinal Diseases | 1 | 2023 | 359 | 0.620 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 153 | 0.620 |
Why?
|
| Stem Cells | 4 | 2024 | 732 | 0.600 |
Why?
|
| Paneth Cells | 1 | 2017 | 26 | 0.550 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 58 | 0.510 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 293 | 0.510 |
Why?
|
| Transplantation, Homologous | 8 | 2024 | 648 | 0.500 |
Why?
|
| Intestines | 2 | 2017 | 611 | 0.490 |
Why?
|
| Smooth Muscle Tumor | 1 | 2014 | 3 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1348 | 0.420 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2014 | 32 | 0.420 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 22 | 0.420 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 42 | 0.420 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 169 | 0.410 |
Why?
|
| Animals | 20 | 2025 | 34996 | 0.410 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 80 | 0.410 |
Why?
|
| Mice | 17 | 2025 | 18572 | 0.400 |
Why?
|
| Vincristine | 1 | 2014 | 195 | 0.400 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 91 | 0.390 |
Why?
|
| Vaginal Neoplasms | 1 | 2012 | 18 | 0.370 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 308 | 0.360 |
Why?
|
| Neutropenia | 2 | 2022 | 205 | 0.350 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 2 | 0.350 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 4 | 0.350 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 672 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2010 | 61 | 0.340 |
Why?
|
| Colitis | 2 | 2023 | 164 | 0.330 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 445 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 98 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 2557 | 0.320 |
Why?
|
| Neoplasms | 2 | 2022 | 2949 | 0.320 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2019 | 4 | 0.300 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 328 | 0.300 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 359 | 0.290 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 300 | 0.280 |
Why?
|
| Humans | 29 | 2025 | 132373 | 0.250 |
Why?
|
| Mucus | 2 | 2022 | 36 | 0.240 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1759 | 0.240 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 807 | 0.240 |
Why?
|
| Mucins | 2 | 2022 | 72 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 1052 | 0.240 |
Why?
|
| Middle Aged | 15 | 2025 | 28895 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 294 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4767 | 0.230 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 9 | 0.220 |
Why?
|
| Bile Ducts | 1 | 2024 | 54 | 0.220 |
Why?
|
| Female | 21 | 2025 | 70809 | 0.210 |
Why?
|
| Immunological Synapses | 1 | 2024 | 30 | 0.210 |
Why?
|
| Feces | 2 | 2024 | 780 | 0.210 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1396 | 0.200 |
Why?
|
| Xylose | 1 | 2022 | 9 | 0.200 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2023 | 107 | 0.190 |
Why?
|
| Carbapenems | 1 | 2022 | 43 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 1409 | 0.190 |
Why?
|
| Biopsy | 2 | 2023 | 1289 | 0.180 |
Why?
|
| Stomach | 1 | 2024 | 273 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 475 | 0.180 |
Why?
|
| Polysaccharides | 1 | 2022 | 148 | 0.180 |
Why?
|
| Fatal Outcome | 2 | 2014 | 377 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 148 | 0.180 |
Why?
|
| Organoids | 1 | 2024 | 301 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 2 | 2015 | 618 | 0.180 |
Why?
|
| Vitamin A | 2 | 2019 | 59 | 0.180 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 2 | 0.180 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2021 | 2 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 242 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 898 | 0.170 |
Why?
|
| Filgrastim | 1 | 2020 | 12 | 0.170 |
Why?
|
| Methylamines | 1 | 2020 | 21 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 499 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 25 | 0.170 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 35 | 0.170 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 425 | 0.160 |
Why?
|
| Ileal Diseases | 1 | 2020 | 28 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1297 | 0.160 |
Why?
|
| Duodenal Diseases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Leukemia | 1 | 2023 | 373 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 127 | 0.160 |
Why?
|
| Ileum | 1 | 2020 | 130 | 0.160 |
Why?
|
| Interleukin-17 | 2 | 2022 | 129 | 0.150 |
Why?
|
| Duodenum | 1 | 2020 | 113 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 691 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 248 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 251 | 0.150 |
Why?
|
| Adult | 10 | 2024 | 31624 | 0.150 |
Why?
|
| Japan | 2 | 2018 | 154 | 0.150 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 9 | 0.150 |
Why?
|
| Macrophages | 2 | 2020 | 693 | 0.150 |
Why?
|
| WT1 Proteins | 1 | 2018 | 24 | 0.150 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2018 | 14 | 0.140 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 17 | 0.140 |
Why?
|
| Cecum | 1 | 2018 | 28 | 0.140 |
Why?
|
| alpha-Defensins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2017 | 38 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4695 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1683 | 0.140 |
Why?
|
| Male | 14 | 2025 | 65072 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 87 | 0.140 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 111 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 47 | 0.130 |
Why?
|
| Metabolomics | 1 | 2021 | 478 | 0.130 |
Why?
|
| Aged | 10 | 2025 | 21386 | 0.130 |
Why?
|
| Lymphoma | 1 | 2020 | 331 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 220 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2018 | 137 | 0.130 |
Why?
|
| Models, Biological | 1 | 2021 | 1458 | 0.120 |
Why?
|
| Remission Induction | 2 | 2018 | 307 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 9949 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 225 | 0.120 |
Why?
|
| Microbiota | 1 | 2021 | 437 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2018 | 248 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2017 | 704 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 217 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2018 | 330 | 0.120 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 287 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 38 | 0.120 |
Why?
|
| Mannans | 1 | 2015 | 15 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2018 | 530 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 63 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 74 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 145 | 0.110 |
Why?
|
| Th17 Cells | 1 | 2015 | 98 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1357 | 0.110 |
Why?
|
| Allografts | 3 | 2020 | 196 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 70 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 56 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 528 | 0.100 |
Why?
|
| Homeostasis | 1 | 2018 | 730 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2013 | 59 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 988 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 252 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 234 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 608 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5405 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 470 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 303 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 571 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 5010 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2014 | 566 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1570 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1368 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2015 | 409 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2020 | 17371 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1723 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1975 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2013 | 508 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 663 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2022 | 104 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2851 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2019 | 127 | 0.070 |
Why?
|
| Mutation | 2 | 2021 | 6250 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2187 | 0.070 |
Why?
|
| Liposomes | 2 | 2019 | 203 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 539 | 0.070 |
Why?
|
| Fibrosis | 2 | 2019 | 428 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2023 | 1229 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2169 | 0.060 |
Why?
|
| Dioxoles | 1 | 2024 | 12 | 0.060 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 21 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 38 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 124 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2024 | 133 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 97 | 0.050 |
Why?
|
| Gene Library | 1 | 2024 | 213 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 15 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 33 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3853 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 57 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 182 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 400 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 506 | 0.040 |
Why?
|
| Time Factors | 1 | 2012 | 6457 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 356 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 1 | 2021 | 3 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2022 | 3873 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20560 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 903 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 675 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 107 | 0.040 |
Why?
|
| Atrophy | 1 | 2020 | 253 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1458 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 140 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 947 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 29 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 100 | 0.040 |
Why?
|
| Hair Follicle | 1 | 2018 | 35 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 20 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2017 | 42 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 42 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 68 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2023 | 748 | 0.030 |
Why?
|
| Lacrimal Apparatus | 1 | 2019 | 128 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 125 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 831 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 156 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 354 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1816 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 263 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3698 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 309 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 956 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 303 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2012 | 13020 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1174 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1303 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 338 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 879 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 419 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 90 | 0.030 |
Why?
|
| Candidiasis | 1 | 2015 | 137 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10912 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 1085 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 544 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 686 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 806 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 539 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2303 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1292 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1881 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6540 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3062 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2687 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7112 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4725 | 0.020 |
Why?
|